| abstract |
The present disclosure describes antibodies, including caninized antibodies against canine PD-L1, having specific properties. This document relates to epitopes of canine PD-L1 that bind to these antibodies, and anti-canine PD-L1 antibodies that bind to these epitopes, and the use of canine anti-canine PD-L1 antibodies in the treatment of canine cancer. . [Selection] Figure 2 |